Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Journal of Pharmacology

• Publication date

  2008-12-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejphar.2008.10.038PMID 18992739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Concepts in Androgen Receptor Blockade

  2008cited by this paper
• Androgen regulation of multidrug resistance‐associated protein 4 (MRP4/ABCC4) in prostate cancer

  2008cited by this paper
• Prostate cancer

  2008cited by this paper
• Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives.

  2008cited by this paper
• The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer

  2008cited by this paper
• In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System

  2008cited by this paper
• The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.

  2007cited by this paper
• Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells.

  2007influential reference
• Androgen-independent prostate cancer.

  2007cited by this paper
• Molecular biology of prostate-cancer pathogenesis

  2006cited by this paper
• Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition.

  2006cited by this paper
• Antiandrogen treatments in locally advanced prostate cancer: are they all the same?

  2006cited by this paper
• Structural basis for antagonism and resistance of bicalutamide in prostate cancer

  2005cited by this paper
• An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes.

  2004cited by this paper
• Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines.

  2004cited by this paper
• Antiproliferative and cytotoxic effects of some σ2 agonists and σ1 antagonists in tumour cell lines

  2004influential reference
• Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence

  2004cited by this paper
• A new mutation of the androgen receptor, P817A, causing partial androgen insensitivity syndrome: in vitro and structural analysis.

  2004cited by this paper
• Success and failure of single-modality treatment for early prostate cancer.

  2004cited by this paper
• The Androgen Receptor: Structure, Mutations, and Antiandrogens

  2003cited by this paper
• Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

  2003cited by this paper
• Biochemical recurrence of prostate cancer.

  2003cited by this paper
• Androgen receptor involvement in the progression of prostate cancer.

  2003cited by this paper
• Androgen Receptor Mutations in Carcinoma of the Prostate

  2001cited by this paper
• Rational use of in vitro P-glycoprotein assays in drug discovery.

  2001cited by this paper
• Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine.

  2001cited by this paper
• Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells.

  2000cited by this paper
• MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines

  2000cited by this paper
• Characterization of MOAT-C and MOAT-D, New Members of the MRP/cMOAT Subfamily of Transporter Proteins

  1999cited by this paper
• Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins.

  1999cited by this paper
• Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins.

  1998cited by this paper
• Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.

  1997cited by this paper
• Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.

  1993cited by this paper
• Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids.

  1990cited by this paper
• Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

  1979cited by this paper

• Assessing the potential for in vivo modulation of FTH1 gene expression with small peptides to restore and enhance androgen receptor pathway inhibition in prostate cancer

  2025cites this paper
• Updates on Overcoming Bicalutamide Resistance: A Glimpse into Resistance to a Novel Antiandrogen.

  2024cites this paper
• Physicochemistry shapes bioactivity landscape of pan-ABC transporter modulators: Anchor point for innovative Alzheimer's disease therapeutics.

  2022cites this paper
• C@PA: Computer-Aided Pattern Analysis to Predict Multitarget ABC Transporter Inhibitors

  2021cites this paper
• Binding mode analysis of ABCA7 for the prediction of novel Alzheimer's disease therapeutics

  2021cites this paper
• Scaffold fragmentation and substructure hopping reveal potential, robustness, and limits of computer-aided pattern analysis (C@PA)

  2021cites this paper
• Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-spectrum ABCB1, ABCC1, and ABCG2 Antagonists.

  2020cites this paper
• Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.

  2020cites this paper
• Nobiletin, a citrus polymethoxyflavone, enhances the effects of bicalutamide on prostate cancer cells via down regulation of NF-κB, STAT3, and ERK activation

  2020cites this paper
• Talazoparib nanoparticles for overcoming multidrug resistance in triple‐negative breast cancer

  2020cites this paper
• Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach.

  2019cites this paper
• 3-benzazecine-based cyclic allene derivatives as highly potent P-glycoprotein inhibitors overcoming doxorubicin multidrug resistance.

  2019cites this paper
• Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.

  2019cites this paper
• A New Class of 1‐Aryl‐5,6‐dihydropyrrolo[2,1‐a]isoquinoline Derivatives as Reversers of P‐Glycoprotein‐Mediated Multidrug Resistance in Tumor Cells

  2018cites this paper
• Androgen receptor-mediated upregulation of quaking affects androgen receptor-related prostate cancer development and anti-androgen receptor therapy

  2018cites this paper
• Polarized macrophage subsets differentially express the drug efflux transporters MRP1 and BCRP, resulting in altered HIV production

  2018cites this paper
• Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agents† †The authors declare no competing interests. ‡ ‡Electronic supplementary information (ESI) available. See DOI: 10.1039/c7md00164a § §This work is dedicated to the memory of Prof. Chris McGuigan, a great

  2017cites this paper
• Rôle du récepteur des xénobiotiques PXR (Pregnane X Receptor) et de ses gènes cibles sur la sensibilité des lignées de cancer de prostate aux inhibiteurs de kinases

  2017cites this paper
• Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.

  2016cites this paper
• The Efflux Transporter ABCG2 Maintains Prostate Stem Cells

  2016cites this paper
• Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.

  2016cites this paper
• Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.

  2016cites this paper
• Advances in plant-based inhibitors of P-glycoprotein

  2016cites this paper
• Insights into Chemoresistance of Prostate Cancer

  2015cites this paper
• Anti-Androgenic Activity of Icarisid II from Epimedium Herb in Prostate Cancer LNCaP Cells.

  2015cites this paper
• Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans.

  2015cites this paper
• Development of β-amino-carbonyl compounds as androgen receptor antagonists

  2014cites this paper
• Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation.

  2013cites this paper
• Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration.

  2013cites this paper
• Predicting substrates of the human breast cancer resistance protein using a support vector machine method

  2013cites this paper
• Regulation, Function, and Clinical Relevance of ABCG2 in Prostate Cancer

  2013cites this paper
• Human ABCG2: structure, function, and its role in multidrug resistance.

  2012cites this paper
• miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2

  2012cites this paper
• Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

  2012cites this paper
• Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents.

  2012cites this paper
• A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.

  2011cites this paper
• Novel potent and selective σ ligands: evaluation of their agonist and antagonist properties.

  2011cites this paper
• Contributions of TM5, ECL3 and TM6 of human BCRP to its oligomerization activities and transport functions

  2011cites this paper
• Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.

  2011cites this paper
• Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins

  2011cites this paper
• Cancer Therapy : Preclinical Lupeol , a Novel Androgen Receptor Inhibitor : Implications in Prostate Cancer Therapy

  2011cites this paper
• New Uses for Old Drugs: Pharmacophore‐Based Screening for the Discovery of P‐Glycoprotein Inhibitors

  2011cites this paper
• Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy

  2011cites this paper
• Bioluminescent mouse models of prostate cancer progression and therapy

  2010cites this paper
• Efflux Pump Inhibitors: A Strategy to Combat P‐Glycoprotein and the NorA Multidrug Resistance Pump

  2010cites this paper
• Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer.

  2010cites this paper
• Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer

  2010cites this paper